Browsing: Swedish Orphan Biovitrum AB

STOCKHOLM, Jan. 5, 2024 /PRNewswire/ — Swedish Orphan Biovitrum AB’s (publ) (Sobi®) (STO: SOBI) (‘Sobi’) Chairman of the Board Bo Jesper…

Sobi plans to publish its report for the third quarter of 2023 on 30 October 2023 at 08:00 CET. STOCKHOLM,…

After 12 weeks, 50% of patients treated with pegcetacoplan showed a reduction in C3c staining by two or more orders…

STOCKHOLM, Sept. 19, 2023 /PRNewswire/ — The subscription period in the rights issue of common shares in Swedish Orphan Biovitrum AB…

STOCKHOLM, July 18, 2023 /PRNewswire/ — The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby…

XTEND-Kids data confirms the efficacy and safety profile of efanesoctocog alfa with 50 IU/kg dosing in previously treated children as…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…

STOCKHOLM, May 19, 2023 /PRNewswire/ — Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a…

Nirsevimab economics simplified through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca Alignment…